GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Lifeline Scientific Inc (LSE:LSI) » Definitions » Cash, Cash Equivalents, Marketable Securities

Lifeline Scientific (LSE:LSI) Cash, Cash Equivalents, Marketable Securities : £5.26 Mil (As of Jun. 2016)


View and export this data going back to . Start your Free Trial

What is Lifeline Scientific Cash, Cash Equivalents, Marketable Securities?

Lifeline Scientific's quarterly cash, cash equivalents, marketable securities increased from Jun. 2015 (£1.96 Mil) to Dec. 2015 (£4.61 Mil) and increased from Dec. 2015 (£4.61 Mil) to Jun. 2016 (£5.26 Mil).

Lifeline Scientific's annual cash, cash equivalents, marketable securities increased from Dec. 2013 (£1.84 Mil) to Dec. 2014 (£2.12 Mil) and increased from Dec. 2014 (£2.12 Mil) to Dec. 2015 (£4.61 Mil).


Lifeline Scientific Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Lifeline Scientific's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lifeline Scientific Cash, Cash Equivalents, Marketable Securities Chart

Lifeline Scientific Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Cash, Cash Equivalents, Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 3.56 1.84 2.12 4.61

Lifeline Scientific Semi-Annual Data
Jun09 Dec09 Jun10 Dec10 Jun11 Dec11 Jun12 Dec12 Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16
Cash, Cash Equivalents, Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.50 2.12 1.96 4.61 5.26

Lifeline Scientific Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.


Lifeline Scientific  (LSE:LSI) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.


Lifeline Scientific Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Lifeline Scientific's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.


Lifeline Scientific (LSE:LSI) Business Description

Industry
Traded in Other Exchanges
N/A
Address
Lifeline Scientific Inc was incorporated on October 1, 1998. The Company is in the business of delivering, to targeted medical markets, a portfolio of related proprietary technologies, which include devices, solutions, and protocols designed to maximize the use and availability of organs, tissues, and cells. It serves the kidney transplant market today with its LifePort product line, and also sells solutions to service the broader organ transplant industry. The Company operates in North America, Brazil, China and Rest of World.